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Can a dietary supplement prevent pre-eclampsia?
L-arginine with vitamins show promise, but there are good grounds for caution
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Pre-eclampsia is a pregnancy syndrome that is defined as the
gestational onset of hypertension and proteinuria; it affects 2-8%
of first time pregnant mothers and has a marked international
variation.1 The highest incidence of maternal mortality as a
result of pre-eclampsia is in Latin America and the Caribbean,
where it accounts for a quarter of maternal deaths.2 Most of
these maternal deaths are caused by uncontrolled hypertension
and multi-organ failure. A simple, cheap, and safe intervention
to prevent pre-eclampsia would have a major impact on global
health. In the linked randomised trial (doi:10.1136/bmj.d2901),
Vadillo-Ortega and colleagues assess whether supplementation
during pregnancy with L-arginine (the substrate for synthesis
of the vasodilatory gas, nitric oxide) and antioxidant vitamins
in a medical food reduces pre-eclampsia in a high risk
population.3
Despite its simple definition, pre-eclampsia is a complex
syndrome with multiple causes that can present with a variety
of clinical features. For this reason, a single treatment is unlikely
to be effective in all women at risk. As our understanding of
pre-eclampsia improves, new therapeutic options emerge. Over
the past 20 years, low dose aspirin and calcium supplements
have had partial success in preventing the development of
pre-eclampsia. Other attempts at preventing pre-eclampsia have
been disappointing, in particular the use of antioxidant vitamins.4
For a healthy pregnancy outcome blood flow must increase to
almost all maternal organs, in particular the uterus and placenta.
Thematernal vasculature dilates in response to increased activity
of the endothelial enzyme nitric oxide synthase.5 This enzyme
produces the vasodilator substance nitric oxide after
stereospecific oxidation of L-arginine. Until recently, it was
thought that L-arginine circulated in such abundance that it
could not be a rate limiting factor for endothelial production of
nitric oxide. However, women with pre-eclampsia have
endothelial damage and raised plasma concentrations of a
competitive inhibitor of nitric oxide synthase, asymmetrical
dimethyl arginine (ADMA).6 In vitro, nitric oxide synthase
activity is inhibited by intracellular ADMA and rescued by
L-arginine supplementation.7 Therefore, L-arginine
supplementation in pregnancy could possibly overcome nitric
oxide synthase inhibition, improvematernal endothelial function,
and reduce the risk of pre-eclampsia.
In Vadillo-Ortega and colleagues’ trial, women at high risk of
pre-eclampsia were randomised to three groups: daily food bars
containing both L-arginine and antioxidant vitamins; bars
containing only vitamins; and bars with neither L-arginine nor
vitamins (placebo).3The intervention started at around 20weeks’
gestation and continued until delivery. The proportion of women
developing pre-eclampsia was 30.2% in the placebo group,
22.5% in the vitamin only group, and 12.7% in the L-arginine
plus vitamin group. The risk ratio was 0.74 (95% confidence
interval 0.54 to 1.02) when comparing the vitamin only group
with the placebo group and 0.42 (0.28 to 0.62) for the L-arginine
plus vitamin group versus the placebo group. L-arginine is a
widely available food supplement so the implications of this
result could be profound. However, several concerns suggest
that a cautious interpretation is warranted.
Firstly, it is not clear how the combination of antioxidant
vitamins and L-arginine led to a reduction in pre-eclampsia.
Crucially, the effects of L-arginine alone were not studied. A
previous trial of L-arginine supplementation for pregnant women
with chronic hypertension showed less need for antihypertensive
agents, but no reduction in the incidence of superimposed
pre-eclampsia.8 Furthermore, women who go on to develop
pre-eclampsia have been found to have higher, not lower, plasma
L-arginine concentrations.9High L-arginine concentrations may
counteract raised ADMA values, but other vasoconstrictor
effects may persist in women who are vulnerable to
pre-eclampsia.9 Vadillo-Ortega and colleagues did not measure
ADMA concentrations.3
Secondly, the primary outcome was classified in a binary
manner. The difference in systolic blood pressure between the
groups (L-arginine plus vitamins v placebo) was 5 mm Hg or
less. The large reduction in relative risk was partly driven by a
small number of women just crossing the diagnostic blood
pressure threshold for pre-eclampsia. Such a simple divide is a
poor reflection of the underlying biology: pre-eclampsia is not
an “all or nothing” disease, and a more nuanced approach
suggests quite modest effects overall.
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A third concern relates to the generalisability of the findings to
women at lower risk and to other settings. Most of the women
in the trial (95%) had a previous pregnancy affected by
pre-eclampsia. Even for such a high risk group, the rate of
pre-eclampsia in the study population was exceptionally high
at 30%, compared with 15% in a similar group in Sweden.10
Beneficial effects of dietary supplements will generally be most
pronounced in people with low levels or deficiency of the food
supplement in question. Interestingly, calcium supplements
reduce the risk of pre-eclampsia in Latin America but not in
North America.11
Other aspects of the trial were commendable. Although opaque
envelopes are not infallible as a means of concealment,
allocation was probably adequately concealed. The study was
designed to be blinded, with nothing to suggest that knowledge
of the randomised allocation affected ascertainment of the
outcome. Outcomeswere ascertained for all women randomised,
and analysis was on an intention to treat basis. Although
non-adherence was common, L-arginine was measured and was
higher in woman randomised to supplements.
Although the findings are important, crucial questions remain.
What is the mechanism of action of L-arginine and vitamins
together; what are the effects (including potential adverse
effects) of L-arginine given alone; what are the effects in other
settings and populations? This is not the conventional “more
research is needed” call. Indeed, a crucial first step before more
trials are started would be a rigorous systematic review of the
numerous inconsistent strands of evidence relating to L-arginine
and its possible effects on pre-eclampsia.
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